Investing

Editas Medicine : EDIT

EDIT

Stock Data

$2.90

$0.10 (3.33%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Editas Medicine Inc is at the forefront of genome editing, pioneering treatments for serious diseases using CRISPR technology. With a focus on developing genomic medicines, its leading projects include EDIT-101 for a rare eye disease and reni-cel for sickle cell disease and beta-thalassemia. The company also explores cancer treatments through engineered T cells. Founded in 2013 and based in Cambridge, Massachusetts, Editas collaborates with industry leaders to advance its mission of transforming medicine.

All Editas Medicine Articles

21 Articles

Rich Duprey | Jun 15, 2025 at 6:34 AM EDT

Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million?

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require…

Rich Duprey | Sep 6, 2024 at 9:54 AM EDT

Buy These 3 Small-Cap Stocks for 90% to 301% Returns

There has been a noticeable shift in the stock market over the last two months. Investors are moving away from…

Trey Thoelcke | Aug 6, 2024 at 9:15 AM EDT

Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024

Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big…

Trey Thoelcke | Feb 29, 2024 at 10:15 AM EST

CEO Dumps 20 Million Ginkgo Bioworks Shares

Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround…

Lee Jackson | Oct 19, 2023 at 9:09 AM EDT

Thursday’s Top Analyst Upgrades and Downgrades: Arm, CrowdStrike, Dow, Hudson Pacific Properties, Lithium Americas, LyondellBasell, Match, Pinterest, Uber and More

Thursday's top analyst upgrades and downgrades included Albemarle, Arm, CrowdStrike, Dow, Fortinet, Hudson Pacific Properties, Lithium Americas, LyondellBasell Industries, Match,…

Lee Jackson | Oct 2, 2023 at 8:44 AM EDT

Monday’s Top Analyst Upgrades and Downgrades: AbbVie, Adobe, Advance Auto Parts, Anheuser-Busch, Bumble, Fortinet, Nike, Palo Alto Networks and More

Monday's top analyst upgrades and downgrades included AbbVie, Adobe, Advance Auto Parts, Anheuser-Busch InBev, Bumble, Fortinet, Nike and Palo Alto…

Lee Jackson | Jun 13, 2023 at 8:51 AM EDT

Tuesday’s Top Analyst Upgrades and Downgrades: Bill, Carnival, Oracle, Palantir, Petrobras, Valvoline, Walmart and More

Tuesday's top analyst upgrades and downgrades included Bill, Carnival, CenterPoint Energy, Editas Medicine, International Paper, Oracle, Palantir Technologies, Petrobras, SentinelOne,…

Lee Jackson | Jun 14, 2022 at 8:50 AM EDT

Tuesday’s Top Analyst Upgrades Downgrades: AMD, American Eagle Outfitters, Coinbase, Dell, Marathon Petroleum, Netflix, Spotify and More

Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, American Eagle Outfitters, Azek, Bausch Health, Coinbase Global, Dell Technologies,…

Chris Lange | Oct 19, 2021 at 3:18 PM EDT

Tuesday Afternoon Analyst Upgrades and Downgrades: CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and More

Tuesday afternoon's analyst upgrades and downgrades included CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and more.

Chris Lange | Sep 24, 2021 at 11:50 AM EDT

Friday Afternoon Analyst Upgrades and Downgrades: Barrick Gold, Newmont, Salesforce and More

Friday afternoon's analyst upgrades and downgrades included Barrick Gold, Canadian National Railway, Community Health Systems, Editas Medicine, Intellia Therapeutics, Newmont…

Chris Lange | Sep 10, 2021 at 9:06 AM EDT

Friday’s Top Analyst Upgrades and Downgrades: American Tower, Best Buy, Beyond Meat, Freeport McMoRan, First Solar, UnitedHealth and More

Friday’s top analyst upgrades and downgrades included American Tower, Best Buy, Beyond Meat, Editas Medicine, Freeport McMoRan, First Solar and…

Chris Lange | Aug 9, 2021 at 12:54 PM EDT

Monday Afternoon Analyst Upgrades and Downgrades: Caesars, Coinbase, Editas, Wynn and More

24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including…

Chris Lange | Aug 5, 2021 at 11:50 AM EDT

Thursday Afternoon Analyst Upgrades and Downgrades: Bath & Body Works, Editas, GoDaddy, PetMed, Qorvo and More

24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Thursday, including…

Chris Lange | Jun 29, 2021 at 8:05 AM EDT

Why Cramer Thinks Companies Should Not Aspire to Meme Stock Status

24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.

Chris Lange | May 4, 2021 at 12:16 PM EDT

Domino’s, Editas, Roblox, Teva, US Steel and More Tuesday Afternoon Analyst Calls

24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Domino’s Pizza,…